Literature DB >> 89047

Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin.

L Fiume, A Mattioli, P G Balboni, M Tognon, G Barbanti-Brodano, J de Vries, T Wieland.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 89047     DOI: 10.1016/0014-5793(79)81247-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


× No keyword cloud information.
  7 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

Review 2.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

3.  Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes.

Authors:  D B Cawley; D L Simpson; H R Herschman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

Review 4.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

5.  Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver.

Authors:  L Fiume; A Mattioli; C Busi; C Accorsi
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

6.  [Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].

Authors:  J Pausch; A Holstege; D Keppler; W Gerok
Journal:  Klin Wochenschr       Date:  1981-06-15

7.  The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells.

Authors:  D Trerè; L Fiume; L B De Giorgi; G Di Stefano; M Migaldi; M Derenzini
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.